ClinicalTrials.gg
CompletedNCT03284853Updated Jan 31, 2022Results posted

Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension

A Phase 3 interventional study of Netarsudil/Latanoprost 0.02%/0.005% and GANFORT® in Open Angle Glaucoma and Ocular Hypertension, sponsored by Aerie Pharmaceuticals. Completed at 68 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-31.

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
436
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies in Glaucoma, Open-Angle by Alcon — 1 open to participants now, 1 under way, none of them phase 3. Glaucoma, Open-Angle · Alcon.

Enrollment
21st of 112
436 · median 154
Started
2017
with 4 others
Phase 3
43 of 126
none open now
Registered
116th of 126
by date

Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 21st largest by enrollment of the 112 interventional ones that give a count, is one of 5 that started in 2017, is one of 43 in phase 3, and was the 116th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 126 studies in Glaucoma, Open-Angle by Alcon is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Glaucoma, Open-Angle by Alcon, or all of them as a file.
02

Study summary

The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular pressure

03

Conditions studied

  • Open Angle Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be 18 years of age or older.
  2. Diagnosis of OAG or OHT in both eyes (OAG in one eye and OHT in the fellow eye is acceptable).
  3. Subjects insufficiently controlled and/or subjects considered in need for combination therapy by the investigators.
  4. Medicated intraocular pressure ≥ 17 mmHg in at least one eye and \< 28mmHg in both eyes at screening visit.
  5. Unmedicated (post-washout) IOP >20mmHg in at least one eye and \< 36mmHg in both eyes at 2 qualification visits at 08:00 hour, 2-7 days apart. At the second qualification visit, have IOP >17mmHg in at least one eye and \< 36mmHg in both eyes at 10:00 and 16:00 hours. Note: For purposes of determining eligibility of subjects to be enrolled, the non-integral IOP mean number will be used. Any non-integral mean IOP number should not be rounded. If only one eye qualifies at the second qualification visit it MUST be the same eye that qualified on the first visit and this will be the study eye for the duration of the study.
  6. Best corrected visual acuity +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200 or better Snellen visual acuity in each eye).
  7. Be able and willing to give signed and follow study instruction.
  8. Women must be either of non-, or women with childbearing potential and men with must be willing to practice acceptable methods of during the study.
  9. Women of childbearing potential must have a negative urine pregnancy test within 7 days of first dose of study treatment and agree to use highly effective contraception during the study and for 3 months after the last dose of study medication.
  10. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use an effective form of contraception from time of randomization and for 3 months following the last dose of study medication.
  11. In France, a subject will be eligible for inclusion in this study only if either affiliated to or as a beneficiary of a social security number.

Exclusion criteria

Exclusion Criteria:

Ophthalmic:

  1. ocular disease (e.g., corneal edema, uveitis, or severe keratoconjunctivitis sicca) which might interfere with interpretation of the study efficacy endpoints or with safety assessments, including subjects with glaucomatous damage so severe that washout of ocular hypotensive medications for 4 weeks or longer if needed is not judged safe as it would put the subject at risk for further vision loss.
  2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles i.e. Grade 2 Shaffer (Chan 1981) or less extreme narrow angle with complete or partial closure. Note: Previous laser peripheral iridotomy is NOT acceptable.
  3. Intraocular pressure ≥ 36mmHg (unmedicated) in either eye (individuals who are excluded for this criterion are not allowed to attempt requalification), or use of more than two ocular hypotensive medications within 30 days of screening. Note: fixed dose combination medications, for the purpose of this exclusion criterion, count as one medication. However, subjects currently taking 2 fixed dose combination products are excluded.
  4. Treatment-naïve subjects.
  5. Prior treatment with GANFORT® topical eye drops where the subjects IOP did not achieve the target IOP and was considered either a therapeutic failure or to have insufficient response. Subjects currently (immediately prior to screening visit) being treated with GANFORT® are excluded from the study.
  6. Known to any component of the formulations to be used (e.g., benzalkonium chloride) or to fluorescein.
  7. Previous glaucoma intraocular surgery, including SLT or in either eye.
  8. Refractive surgery in either eye (e.g., radial keratotomy, PRK, LASIK, corneal cross-linking, keratoplasty).
  9. Ocular trauma within the six months prior to screening, or ocular surgery or non-refractive laser treatment within the three months prior to screening.
  10. Recent or current evidence of ocular infection or inflammation in either eye. Current evidence of clinically significant blepharitis, conjunctivitis, keratitis, current evidence or history of herpes simplex or zoster keratitis in either eye at screening.
  11. Use of ocular medication in either eye of any kind within 30 days of screening and throughout the study, with the exception of a) ocular hypotensive medications which must have been the same medication for 30 days prior to screening (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after, screening), c) lubricating drops for dry eye (which may be used throughout the study), as prescribed by the Investigator.
  12. Mean central corneal thickness greater than 620μm at screening.
  13. Any abnormality preventing reliable Goldmann applanation tonometry of either eye (e.g., keratoconus).

    Systemic:

  14. Clinically significant abnormalities in laboratory tests at screening.
  15. Known hypersensitivity or to GANFORT® (Appendix 3 Marketed Product Medication Information Section 4.3) and to β-adrenoceptor antagonists (e.g. or bronchial asthma; abnormally low blood pressure or heart rate; second or third-degree heart block or congestive heart failure, cardiac failure, cardiac shock and severe diabetes).
  16. Clinically significant systemic disease which might interfere with the study.
  17. Participation in any investigational study within 30 days prior to screening.
  18. Systemic medication including containing drugs that could have a substantial effect on IOP which HAVE NOT been maintained at a consistent dose and regime within 30 days prior to screening, and are anticipated to change in dose and/or regime during the study.
  19. Use of topical steroid containing medications on the face or in or around the eyes will exclude the subject (see Section 5.6 Concomitant Medications).
  20. Women of who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable and highly effective form of . An adult woman is considered to be of childbearing potential unless she is one year (1 year without menses with appropriate clinical profile, e.g. age appropriate, > 45 years in the absence of HRT. In questionable cases the subject must have FSH value > 40mIU/mL and an estradiol value \< 40pg/mL (\< 140pmol/L)) or three months post-surgical sterilization.
  21. Vulnerable subjects such as minors, adults under legal protection or unable to express their consent (e.g. hospitalized persons in coma), persons deprived of liberty (prisoners from jails), or persons subject to psychiatric care.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
436 participants (actual)

Study arms

  • Experimental
    Netarsudil/Latanoprost 0.02%/0.005%

    PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.

    Drug: Netarsudil/Latanoprost 0.02%/0.005%

  • Active comparator
    GANFORT®

    GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.

    Drug: GANFORT®

Interventions

  • DrugNetarsudil/Latanoprost 0.02%/0.005%

    Topical sterile ophthalmic solution

  • Topical sterile ophthalmic solution

06

What researchers measure

Primary outcomes

  1. Mean Diurnal Intraocular Pressure by Goldmann Applanation Tonometry

    Comparison of PG324 to Ganfort for mean intraocular pressure at specified timepoints at Week 2, Week 6 and Month 3.

    Time frame: Day 90

07

Results

Posted Jan 19, 2022

Participant flow

Recruitment took place in 11 European countries between September 2017 and May 2020.

Participant flow — Overall Study
MilestoneNetarsudil/Latanoprost 0.02%/0.005%GANFORT®
Started218212
Intent-to-treat population218212
Per-protocol population169170
Safety population218212
Completed163199
Not completed5513
Withdrew: Adverse event404
Withdrew: Withdrawal by subject51
Withdrew: Lost to follow-up10
Withdrew: Lack of efficacy10
Withdrew: Disallowed concurrent medication11
Withdrew: Protocol violation33
Withdrew: Death01
Withdrew: Other - reason not reported in csr43

Outcome measures

PrimaryMean Diurnal Intraocular Pressure by Goldmann Applanation Tonometry

Comparison of PG324 to Ganfort for mean intraocular pressure at specified timepoints at Week 2, Week 6 and Month 3.

Time frame:
Day 90
Reported as:
Least squares mean · mmHg
Mean Diurnal Intraocular Pressure by Goldmann Applanation Tonometry
mmHgNetarsudil/Latanoprost 0.02%/0.005%GANFORT®
Week 215.39 (15.09 to 15.84)15.56 (15.42 to 15.67)
Week 615.64 (15.18 to 16.20)15.25 (15.16 to 15.32)
Month 315.61 (15.28 to 15.93)15.19 (15.09 to 15.27)
Statistical analysis
  • Netarsudil/Latanoprost 0.02%/0.005% vs GANFORT® · Regression, Linear · p = <0.05 (Linear model with IOP at the given visit and time point as the response, baseline IOP as a covariate, and treatment as a main effect factor at each time point (08:00, 10:00, and 16:00 hours at the Week 2, Week 6, and Month 3 Visits).)Non-inferiority for PG324 was concluded if the UL of the 95% CI was ≤ l.5 mmHg at all 9 time points and ≤ l.0 mmHg at the majority of time points

Adverse events

Collected over Adverse events were documented for each participant from the time of signing consent until 30 days after the last dose of Investigational Product. This was a maximum period of approximately 9 months (38 weeks) for participants who completed the full study duration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Netarsudil/Latanoprost 0.02%/0.005%0/218 (0%)7/218 (3.2%)117/218 (53.7%)
GANFORT®1/212 (0.5%)7/212 (3.3%)53/212 (25%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventNetarsudil/Latanoprost 0.02%/0.005%GANFORT®
CholecystitisHepatobiliary disorders2/2180/212
Accidental poisoningInjury, poisoning and procedural complications0/2181/212
Road traffic accidentInjury, poisoning and procedural complications0/2181/212
Metastases to lungNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2181/212
Facial paralysisNervous system disorders0/2181/212
Ischemic strokeNervous system disorders0/2181/212
Cardiac failureCardiac disorders0/2181/212
Dermoid cystCongenital, familial and genetic disorders0/2181/212
Lower respiratory tract infectionInfections and infestations0/2181/212
PneumoniaInfections and infestations0/2181/212
Most frequent other events
Most frequent other events
EventNetarsudil/Latanoprost 0.02%/0.005%GANFORT®
Conjunctival HyperemiaEye disorders72/21823/212
Cornea VerticillataEye disorders24/2180/212
Conjunctival HemorrhageEye disorders18/2185/212
HypertensionVascular disorders10/21817/212
Eye PruritusEye disorders17/2184/212
Punctate KeratitisEye disorders12/2185/212
Conjunctivitis AllergicEye disorders12/2181/212
Viral Upper Respiratory Tract InfectionInfections and infestations11/21810/212

Baseline characteristics

436 participants were randomized; 220 to the Netarsudil/Latanoprost 0.02%/0.005% arm and 216 to the Ganfort arm. From the total 436 participants, 6 were not included in the analysis due to serious GCP breaches (see Pre-Assignment Details for more information).

Age, Categorical
Age, Categorical(Participants)Netarsudil/Latanoprost 0.02%/0.005%GANFORT®Total
<=18 years000
Between 18 and 65 years7179150
>=65 years147133280
Age, Continuous
Age, Continuous(years)Netarsudil/Latanoprost 0.02%/0.005%GANFORT®Total
Mean67.3 (25 to 91)67.0 (22 to 91)67.2 (22 to 91)
Sex: Female, Male
Sex: Female, Male(Participants)Netarsudil/Latanoprost 0.02%/0.005%GANFORT®Total
Female13192223
Male87120207
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Netarsudil/Latanoprost 0.02%/0.005%GANFORT®Total
Hispanic or Latino6156117
Not Hispanic or Latino157156313
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Netarsudil/Latanoprost 0.02%/0.005%GANFORT®Total
American Indian or Alaska Native000
Asian033
Native Hawaiian or Other Pacific Islander000
Black or African American459
White210200410
More than one race000
Unknown or Not Reported448
Region of Enrollment
Region of Enrollment(participants)Netarsudil/Latanoprost 0.02%/0.005%GANFORT®Total
Austria171734
Latvia8816
Belgium5510
Hungary81119
Czechia303161
Poland336
Italy212142
United Kingdom201535
France246
Germany383674
Spain6661127
08

Study locations

68 sites
  • State Hospital - University Medical Center Academical Department of Ophthalmology
    Graz, Austria
  • Albertgasse 39/10+11
    Vienna, Austria
  • Hanusch Hospital
    Vienna, Austria
  • UZ Leuven, campus Gasthuisberg, Herestraat 49, 3000 Leuven
    Leuven, Belgium
  • Faculty Hospital Brno Eye Department
    Brno, 62500, Czechia
  • Glaucoma center Oční klinika VFN a 1. LF UK
    Praha, 12808, Czechia
  • Ophthalmology Service Centre Francois Xavier Michelet CHU Pellegrin
    Bordeaux, France
  • Centre ophtalmologique Pole vision val d'ouest
    Ecully, France
  • Ophthalmology Service - Batiment R Hospital de la Croix-Rousse
    Lyon, France
  • CHU de Nantes-Hospital Hotel Dieu Ophthalmology Service
    Nantes, France
  • Ophthalmology department Necker University Hospital-Enfants Malades
    Paris, France
  • University Medical Center Freiburg, Eye Center,Killianstr.5, Freiburg i. Breisgau
    Freiburg, 79106, Germany
  • Department of Ophthalmology Clinical Johannes Gutenberg-University Mainz
    Mainz, Germany
  • Universitats-Augenklinik, Studienzentrum/Clinical Trials in Opthalmology (CTO)
    Münster, Germany
  • University Eye Hospital Tuebingen, STC eyetrial at the center for Ophthalmolgy
    Tuebingen, Germany
  • Augenarztpraxis Dr. Andreas Bayer
    Weilheim, Germany
  • Budapest Retina Associates
    Budapest, Hungary
  • Department of Ophthalmology Semmelweis University
    Budapest, Hungary
  • University of Debrecen, Clinical Center, Ophthalmology Department
    Debrecen, Hungary
  • Clinexpert Gyongyos Kft.
    Heves, Hungary
  • Ganglion Medical Center
    Pécs, Hungary
  • University of Szeged, Department of Ophthalmology
    Szeged, Hungary
  • Markusovszky University Teaching Hospital
    Szombathely, Hungary
  • Ophthalmic Clinic DiNOGMI University Hospital San Martino
    Genova, Italy
  • Dept. Ophthalmology, San Raffaele Hospital
    Milano, Italy
  • ASST Fatebenefratelli Sacco P.O.L.Sacco
    Milan, Italy
  • ASST Santi Paolo e Carlo - Ophthalmic Clinic
    Milan, Italy
  • Department of Medicine and Surgery University of Parma
    Parma, Italy
  • Ophthamic Clinic of the University of Pavia, IRCCS Foundation San Matteo Policlinic
    Pavia, Italy
  • AOU Pisana Hospital of Cisanello
    Pisa, Italy
  • G.B.Bietti Foundation - IRCCS
    Rome, Italy
  • Senese University Hospital
    Siena, Italy
  • S.C.U Oculistica, Azienda Ospedaliero Universitaria, Città della Salute e della Scienza
    Torino, 10146, Italy
  • University Eye Clinic Ospedale Maggiore
    Trieste, Italy
  • Politecnico Gianbattista Rossi AOUI Ospedale Borgo Roma
    Verona, Italy
  • Signes Ozolinas Doctor Practice in Ophthalmology
    Jelgava, Latvia
  • Latvian American Eye Centre (LAAC)
    Riga, Latvia
  • P.Stradins Clinical University Hospital, Ophthalmology Clinic
    Riga, Latvia
  • Riga East University hospital, In-patient Department "Biķernieki", Ophthalmology Clinic
    Riga, Latvia
  • Professor K. Gibinski University Clinical Centre
    Katowice, Poland
  • Department of Diagnostics and Microsurgery of Glaucoma
    Lublin, Poland
  • Military Institute of Medicine Klinika Okulistyki
    Warsaw, Poland
  • Ophthalmic Clinic Jasne Blonia
    Łódź, Poland
  • Centro de Oftalmologia Barraquer
    Barcelona, Spain
  • Hospital General de Catalunya Ophthalmology Department
    Barcelona, Spain
  • Hospital QuironSalud Barcelona
    Barcelona, Spain
  • Institut Catala de retina (ICR) Glaucoma and Investigation Department
    Barcelona, Spain
  • Hospital General del S.A.S. de Jerez de la Frontera
    Cádiz, 11407, Spain
  • Hospital Universitario Reina Sofía de Córdoba
    Córdoba, Spain
  • Centro de Ojos de la Coruña
    La Coruña, Spain
  • Hospital Universitario Virgen Macarena Ophthalmology Department
    Sevilla, Spain
  • Hospital Universitario de Torrevieja Ophthalmology Department
    Torrevieja, Spain
  • FISABIO-Oftalmología Médica
    Valencia, Spain
  • Ophthalmology Department Hospital Universitario Rio Hortega
    Valladolid, Spain
  • Hospital Clinico Universitario Lozano Blesa Zaragoza Ophthalmology department
    Zaragoza, Spain
  • Hospital Universitario Miguel Servet Ophthalmology Department
    Zaragoza, Spain
  • City Hospitals Sunderland NHS Foundation Trust Sunderland Eye Infirmary
    Sunderland, Tyne And Wear, United Kingdom
  • NHS Grampian Aberdeen Royal Infirmary
    Aberdeen, United Kingdom
  • Cambridge University Hospitals NHS Trust
    Cambridge, United Kingdom
  • Ophthalmology Department, Queen Alexandra Hospital
    Cosham, United Kingdom
  • Mid-Cheshire Hospitals NHS Foundation Trust
    Crewe, United Kingdom
  • Northwest Anglia NHS Foundation trust Hinchingbrooke Hospital
    Huntingdon, United Kingdom
  • Guy's & St Thomas' NHS Foundation Trust Glaucoma Research Area
    London, United Kingdom
  • King's College Hospital
    London, United Kingdom
  • Moorfields Eye Hospital NHS
    London, United Kingdom
  • Western Eye Hospital
    London, United Kingdom
  • Royal Hallamshire Hospital
    Sheffield, United Kingdom
  • Queen Mary Hospital, King's College Hospital NHS
    Sidcup, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Nov 2020, 38 months.

Results were first posted in Jan 2022, 1 year 2 months after primary completion.

Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 38 months is above that.

Counting every sponsor, half of 49 studies reached it within 25 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2017
First posted
Sep 15, 2017
StartActual
Sep 5, 2017
Primary completionActual
Nov 6, 2020
CompletionActual
Nov 6, 2020
Results first posted
Jan 19, 2022
Last update
Jan 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03284853
Responsible party
Sponsor
First posted
Sep 15, 2017
Start date
Sep 5, 2017
Primary completion
Nov 6, 2020
Completion
Nov 6, 2020
Results posted
Jan 19, 2022
Last update
Jan 31, 2022

Study contacts

Michelle Senchyna
study director · Aerie Pharmaceuticals Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion